Anixa Biosciences Stock News

Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Anixa Biosciences (ANIX) has added ~6.5% in the pre-market after announcing that in early lab studies, a molecule developed by the company and partner MolGenie GmbH was more potent…

Anixa Biosciences Inc (ANIX) shares closed today at 1.5% above its 52 week low of $2.74, giving the company a market cap of $83M. The stock is currently down 6.4% year-to-date, down 18.7% over the past 12 months, and down 48.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 17.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -563.0% The company's stock price performance over the past 12 months lags the peer average by 210.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Anixa Biosciences Inc. (NASDAQ:ANIX) price closed higher on Tuesday, December 07, jumping 3.35% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

Anixa Biosciences Inc (NASDAQ: ANIX ) announced the results of a genomic variant analysis conducted with its partner, MolGenie GmbH , on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant, in addition to the previously identified Delta variant Full story available on Benzinga.com

In the latest trading session, 0.84 million Anixa Biosciences Inc. (NASDAQ:ANIX) shares changed hands as the companys beta touched 1.75. With the companys most recent per share price at $3.37 changing hands around $0.24 or 7.67% at last look, the market valuation stands at $97.66M. ANIXs current price is a discount, trading about -140.06% off Anixa Biosciences Inc. (NASDAQ: ANIX): The Stock For Success Over The Next Few Months Read More »

Brokerages expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to announce earnings per share of ($0.09) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Anixa Biosciences earnings. Anixa Biosciences reported earnings per share of ($0.81) in the same quarter last year, which suggests a positive year-over-year growth rate of 88.9%. The business []

Wall Street brokerages expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to report earnings of ($0.09) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Anixa Biosciences earnings. Anixa Biosciences reported earnings per share of ($0.81) in the same quarter last year, which would suggest a positive year over year growth rate []

Wealth Alliance Advisory Group LLC acquired a new position in shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,413 shares of the companys stock, valued at approximately $78,000. Other institutional investors and hedge []

SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, anno

SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced t

SAN JOSE, Calif., Sept. 8, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced t

SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced tod

SAN JOSE, Calif., Aug. 30, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced t